| Basics |
Sage Therapeutics, Inc.
Sage Therapeutics Inc is a biopharmaceutical company conducting development programs and clinical trials to discover medicines for central nervous system disorders. It has development programs for refractory status epilepticus, and Parkinson's di-sease.
|
| IPO Date: |
July 18, 2014 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$544.94M |
| Activated in VL: |
False |
| Average Daily Range |
| Avg Daily Range: |
$1.52 | 2.53%
|
| Avg Daily Range (30 D): |
$0.04 | 0.45%
|
| Avg Daily Range (90 D): |
$0.12 | 1.65%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.62M |
| Avg Daily Volume (30 D): |
2.08M |
| Avg Daily Volume (90 D): |
1.67M |
| Trade Size |
| Avg Trade Size (Sh.): |
80 |
| Avg Trade Size (Sh.) (30 D): |
259 |
| Avg Trade Size (Sh.) (90 D): |
159 |
| Institutional Trades |
| Total Inst.Trades: |
5,349 |
| Avg Inst. Trade: |
$2.68M |
| Avg Inst. Trade (30 D): |
$2.76M |
| Avg Inst. Trade (90 D): |
$2.02M |
| Avg Inst. Trade Volume: |
.06M |
| Avg Inst. Trades (Per Day): |
2 |
| Market Closing Trades |
| Avg Closing Trade: |
$3.72M |
| Avg Closing Trade (30 D): |
$6.32M |
| Avg Closing Trade (90 D): |
$2.91M |
| Avg Closing Volume: |
89.67K |
|
|
| Financials |
| |
TTM |
Q1 2025 |
Q4 2024 |
|
Basic EPS
|
$-.79
|
$-1.01
|
$-1.56
|
|
Diluted EPS
|
$-.79
|
$-1.01
|
$-1.56
|
|
Revenue
|
$ 31.66M
|
$ 14.06M
|
$ 12.82M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$ -49.65M
|
$ -62.21M
|
$ -95.78M
|
|
Operating Income / Loss
|
$ -53.97M
|
$ -67.46M
|
$ -102.19M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$ 22.26M
|
$ -35.8M
|
$ -19.99M
|
|
PE Ratio
|
|
|
|
|
|
|
